How oliceridine (TRV-130) binds and stabilizes a μ-opioid receptor conformational state that selectively triggers G protein signaling pathways

Biochemistry

Volumn 55, Issue 46, 2016, Pages 6456-6466

  Schneider, Sebastian ^a   Provasi, Davide ^a   Filizola, Marta ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL ATOMIC STRUCTURE; CRYSTAL STRUCTURE; LIGANDS; MOLECULAR DYNAMICS; PROTEINS;

ALLOSTERIC MODULATION; CONFORMATIONAL STATE; INFORMATION TRANSFERS; LIGAND-RECEPTOR INTERACTIONS; MOLECULAR DYNAMICS SIMULATIONS; OPIOID ANALGESICS; RESPIRATORY DEPRESSION; STRUCTURE-BASED DESIGNS;

BINS;

GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; MU OPIATE RECEPTOR; OLICERIDINE; ((3-METHOXYTHIOPHEN-2-YL)METHYL)((2-(9-(PYRIDIN-2-YL)-6-OXASPIRO(4.5)DECAN-9-YL)ETHYL))AMINE; AMINO ACID; LIGAND; OPRM1 PROTEIN, HUMAN; SPIRO COMPOUND; THIOPHENE DERIVATIVE;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; ENERGY TRANSFER; LIGAND BINDING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; GENETICS; HUMAN; KINETICS; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STABILITY;

AMINO ACIDS; BINDING SITES; BINDING, COMPETITIVE; CRYSTALLIZATION; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN DOMAINS; PROTEIN STABILITY; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS; THIOPHENES;

EID: 84997830677     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/acs.biochem.6b00948     Document Type: Article

References (49)

1. Walwyn, W. M., Miotto, K. A., and Evans, C. J. (2010) Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions Drug Alcohol Depend. 108, 156-165 10.1016/j.drugalcdep.2010.01.001
2. Results from the 2009 National Survey on Drug Use and Health: Vol. I. Summary of National Findings (2010) Office of Applied Studies, National Survey on Drug Use and Health, Rockville, MD.
3. Kieffer, B. L. (1999) Opioids: first lessons from knockout mice Trends Pharmacol. Sci. 20, 19-26 10.1016/S0165-6147(98)01279-6
4. Raehal, K. M., Walker, J. K., and Bohn, L. M. (2005) Morphine side effects in beta-arrestin 2 knockout mice J. Pharmacol. Exp. Ther. 314, 1195-1201 10.1124/jpet.105.087254
5. Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., and Lin, F. T. (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2 Science 286, 2495-2498 10.1126/science.286.5449.2495
6. Maguma, H. T., Dewey, W. L., and Akbarali, H. I. (2012) Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice Eur. J. Pharmacol. 685, 133-140 10.1016/j.ejphar.2012.04.001
7. Kenakin, T. (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism Nat. Rev. Drug Discovery 4, 919-927 10.1038/nrd1875
8. Kenakin, T. (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors Trends Pharmacol. Sci. 28, 407-415 10.1016/j.tips.2007.06.009
9. Kenakin, T. (2009) Biased agonism F1000 Biol. Rep. 1, 87 10.3410/B1-87
10. Mailman, R. B. (2007) GPCR functional selectivity has therapeutic impact Trends Pharmacol. Sci. 28, 390-396 10.1016/j.tips.2007.06.002
11. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2006) Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320, 1-13 10.1124/jpet.106.104463
12. Bohn, L. M. (2009) Selectivity for G protein or arrestin-mediated signaling. In Functional Selectivity of G Protein-Coupled Receptor Ligands (Neve, K., Ed.) pp 71-85, Humana Press, Totowa, NJ.
13. Raehal, K. M. and Bohn, L. M. (2014) Beta-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia Handb. Exp. Pharmacol. 219, 427-443 10.1007/978-3-642-41199-1-22
14. Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., and Bohn, L. M. (2006) An opioid agonist that does not induce mu-opioid receptor - arrestin interactions or receptor internalization Mol. Pharmacol. 71, 549-557 10.1124/mol.106.028258
15. Lamb, K., Tidgewell, K., Simpson, D. S., Bohn, L. M., and Prisinzano, T. E. (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology Drug Alcohol Depend. 121, 181-188 10.1016/j.drugalcdep.2011.10.026
16. Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., Huang, X. P., Sassano, M. F., Giguère, P. M., Löber, S., Da Duan, Scherrer, G., Kobilka, B. K., Gmeiner, P., Roth, B. L., and Shoichet, B. K. (2016) Structure-based discovery of opioid analgesics with reduced side effects Nature 537, 185-190 10.1038/nature19112
17. DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X. T., Pitis, P. M., Gotchev, D., Yuan, C., Koblish, M., Lark, M. W., and Violin, J. D. (2013) A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J. Pharmacol. Exp. Ther. 344, 708-717 10.1124/jpet.112.201616
18. Chen, X. T., Pitis, P., Liu, G., Yuan, C., Gotchev, D., Cowan, C. L., Rominger, D. H., Koblish, M., Dewire, S. M., Crombie, A. L., Violin, J. D., and Yamashita, D. S. (2013) Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain J. Med. Chem. 56, 8019-8031 10.1021/jm4010829
19. Soergel, D. G., Subach, R. A., Sadler, B., Connell, J., Marion, A. S., Cowan, C. L., Violin, J. D., and Lark, M. W. (2014) First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers J. Clin. Pharmacol. 54, 351-357 10.1002/jcph.207
20. Viscusi, E. R., Webster, L., Kuss, M., Daniels, S., Bolognese, J. A., Zuckerman, S., Soergel, D. G., Subach, R. A., Cook, E., and Skobieranda, F. (2016) A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain Pain 157, 264-272 10.1097/j.pain.0000000000000363
21. Soergel, D. G., Subach, R. A., Burnham, N., Lark, M. W., James, I. E., Sadler, B. M., Skobieranda, F., Violin, J. D., and Webster, L. R. (2014) Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers Pain 155, 1829-1835 10.1016/j.pain.2014.06.011
22. Healy, J. R., Bezawada, P., Shim, J., Jones, J. W., Kane, M. A., MacKerell, A. D., Jr., Coop, A., and Matsumoto, R. R. (2013) Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed mu agonist/delta antagonist opioid analgesic with reduced tolerance liabilities ACS Chem. Neurosci. 4, 1256-1266 10.1021/cn4000428
23. Thompson, G. L., Kelly, E., Christopoulos, A., and Canals, M. (2015) Novel GPCR paradigms at the μ-opioid receptor Br. J. Pharmacol. 172, 287-296 10.1111/bph.12600
24. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) Crystal structure of the micro-opioid receptor bound to a morphinan antagonist Nature 485, 321-326 10.1038/nature10954
25. Huang, W., Manglik, A., Venkatakrishnan, A. J., Laeremans, T., Feinberg, E. N., Sanborn, A. L., Kato, H. E., Livingston, K. E., Thorsen, T. S., Kling, R. C., Granier, S., Gmeiner, P., Husbands, S. M., Traynor, J. R., Weis, W. I., Steyaert, J., Dror, R. O., and Kobilka, B. K. (2015) Structural insights into mu-opioid receptor activation Nature 524, 315-321 10.1038/nature14886
26. Mackerell, A. D., Jr., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, T. K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, B., Smith, J., Stote, R., Straub, J., Watanabe, M., Wiorkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102, 3586-3616 10.1021/jp973084f
27. Best, R. B., Zhu, X., Shim, J., Lopes, P. E. M., Mittal, J., Feig, M., and MacKerell, A. D., Jr. (2012) Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi1 and chi2 dihedral angles J. Chem. Theory Comput. 8, 3257-3273 10.1021/ct300400x
28. Klauda, J. B., Venable, R. M., Freites, J. A., O'Connor, J. W., Tobias, D. J., Mondragon-Ramirez, C., Vorobyov, I., MacKerell, A. D., Jr., and Pastor, R. W. (2010) Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types J. Phys. Chem. B 114, 7830-7843 10.1021/jp101759q
29. Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., and Mackerell, A. D., Jr. (2010) CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields J. Comput. Chem. 31, 671-690 10.1002/jcc.21367
30. Abraham, M., Murtola, T., Schulz, R., Páll, S., Smith, J., Hess, B., and Lindahl, E. (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers SoftwareX 1-2, 19-25 10.1016/j.softx.2015.06.001
31. Shaw, D., Deneroff, M., Dror, R., Kuskin, J., Larson, R., Salmon, J., Young, C., Batson, B., Bowers, K., Chao, J. C., Eastwood, M., Gagliardo, J., Grossman, J., Ho, C., Lerardi, J., Kolossváry, I., Klepeis, J., Layman, T., McLeavey, C., Moraes, M., Mueller, R., Priest, E., Shan, Y., Spengler, J., Theobald, M., Towles, B., and Wang, S. (2008) Anton, A Special-Purpose Machine for Molecular Dynamics Simulation Commun. ACM 51, 91-97 10.1145/1364782.1364802
32. Bussi, G., Donadio, D., and Parrinello, M. (2007) Canonical sampling through velocity rescaling J. Chem. Phys. 126, 014101 10.1063/1.2408420
33. Parrinello, M. and Rahman, A. (1981) Polymorphic transitions in single crystals: A new molecular dynamics method J. Appl. Phys. 52, 7182 10.1063/1.328693
34. Hoover, W. G. (1985) Canonical dynamics: Equilibrium phase-space distributions Phys. Rev. A: At. Mol. Opt. Phys. 31, 1695-1697 10.1103/PhysRevA.31.1695
35. Martyna, G., Klein, M., and Tuckerman, M. (1992) Nosé-Hoover chains: the canonical ensemble via continuous dynamics J. Chem. Phys. 97, 2635-2643 10.1063/1.463940
36. Shan, Y., Klepeis, J., Eastwood, M., Dror, R., and Shaw, D. (2005) Gaussian split Ewald: A fast Ewald mesh method for molecular simulation J. Chem. Phys. 122, 054101 10.1063/1.1839571
37. Sander, J., Ester, M., Kriegel, H.-P., and Xu, X. (1998) Density-based clustering in spatial databases: the algorithm GDBSCAN and its applications Data Mining and Knowledge Discovery 2, 169-194 10.1023/A:1009745219419
38. Scherer, M. K., Trendelkamp-Schroer, B., Paul, F., Perez-Hernandez, G., Hoffmann, M., Plattner, N., Wehmeyer, C., Prinz, J. H., and Noé, F. (2015) PyEMMA 2: A software package for estimation, validation, and analysis of Markov models J. Chem. Theory Comput. 11, 5525-5542 10.1021/acs.jctc.5b00743
39. LeVine, M. V. and Weinstein, H. (2014) NbIT - a new information theory-based analysis of allosteric mechanisms reveals residues that underlie function in the leucine transporter LeuT PLoS Comput. Biol. 10, e1003603 10.1371/journal.pcbi.1003603
40. Glykos, N. M. (2006) Carma: a molecular dynamics analysis program J. Comput. Chem. 27, 1765-1768 10.1002/jcc.20482
41. Gokhale, D. and Ahmed, N. (1989) Entropy Expressions and Their Estimators for Multivariate Distributions IEEE Trans. Inf. Theory 35, 688-692 10.1109/18.30996
42. Granier, S. and Kobilka, B. (2012) A new era of GPCR structural and chemical biology Nat. Chem. Biol. 8, 670-673 10.1038/nchembio.1025
43. Mondal, J., Friesner, R. A., and Berne, B. J. (2014) Role of desolvation in thermodynamics and kinetics of ligand binding to a kinase J. Chem. Theory Comput. 10, 5696-5705 10.1021/ct500584n
44. Tiwary, P., Mondal, J., Morrone, J. A., and Berne, B. J. (2015) Role of water and steric constraints in the kinetics of cavity-ligand unbinding Proc. Natl. Acad. Sci. U. S. A. 112, 12015-12019 10.1073/pnas.1516652112
45. Young, T., Hua, L., Huang, X., Abel, R., Friesner, R., and Berne, B. J. (2010) Dewetting transitions in protein cavities Proteins: Struct. Funct. Genet. 78, 1856-1869 10.1002/prot.22699
46. Dror, R. O., Pan, A. C., Arlow, D. H., Borhani, D. W., Maragakis, P., Shan, Y., Xu, H., and Shaw, D. E. (2011) Pathway and mechanism of drug binding to G-protein-coupled receptors Proc. Natl. Acad. Sci. U. S. A. 108, 13118-13123 10.1073/pnas.1104614108
47. Katritch, V., Cherezov, V., and Stevens, R. C. (2013) Structure-function of the G-protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 53, 531 10.1146/annurev-pharmtox-032112-135923
48. Fenalti, G., Giguere, P. M., Katritch, V., Huang, X. P., Thompson, A. A., Cherezov, V., Roth, B. L., and Stevens, R. C. (2014) Molecular control of delta-opioid receptor signalling Nature 506, 191-196 10.1038/nature12944
49. Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., Javitch, J. A., Christopoulos, A., and Lane, J. R. (2016) The role of kinetic context in apparent biased agonism at GPCRs Nat. Commun. 7, 10842 10.1038/ncomms10842